scholarly article | Q13442814 |
P50 | author | Dawn Quelle | Q42576515 |
Kimberly K Leslie | Q56915077 | ||
Xiangbing Meng | Q59680607 | ||
Eric J Devor | Q91064844 | ||
P2093 | author name string | Shujie Yang | |
Shaikamjad Umesalma | |||
Yujun Li | |||
Kristina W Thiel | |||
William H Thiel | |||
Xinhao Wang | |||
Yiyang Li | |||
Jianling Bi | |||
P2860 | cites work | Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | Q40169580 |
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells | Q40310345 | ||
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin | Q40336893 | ||
Gain of function mutations in p53. | Q41557652 | ||
Molecular sequelae of histone deacetylase inhibition in human malignant B cells | Q44280918 | ||
Synthetically lethal nanoparticles for treatment of endometrial cancer. | Q47370432 | ||
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies | Q60200233 | ||
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects | Q73212118 | ||
DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization | Q24302100 | ||
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation | Q24337242 | ||
The DNA-damage response in human biology and disease | Q24606586 | ||
Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
Thermodynamic stability of wild-type and mutant p53 core domain | Q24648879 | ||
Spotlight on ixazomib: potential in the treatment of multiple myeloma | Q26774440 | ||
Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
The role of p53 in cancer drug resistance and targeted chemotherapy | Q28072553 | ||
The DNA damage response: ten years after | Q28261230 | ||
Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
Cell-cycle checkpoints and cancer | Q28293996 | ||
Mutational landscape and significance across 12 major cancer types | Q28300353 | ||
ATM and related protein kinases: safeguarding genome integrity | Q29547735 | ||
Chk1 and Chk2 kinases in checkpoint control and cancer | Q29617706 | ||
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. | Q30538161 | ||
Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. | Q30804251 | ||
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33431778 | ||
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function | Q33825046 | ||
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. | Q33931140 | ||
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | Q34775855 | ||
The oncogenic roles of p53 mutants in mouse models | Q36701574 | ||
Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? | Q36823657 | ||
CDC25 phosphatases in cancer cells: key players? Good targets? | Q36849329 | ||
Chaperone-mediated autophagy degrades mutant p53. | Q37098172 | ||
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat | Q37199772 | ||
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. | Q37402942 | ||
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53 | Q37411955 | ||
When mutants gain new powers: news from the mutant p53 field. | Q37582777 | ||
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo | Q38411451 | ||
Integrating genetic approaches into the discovery of anticancer drugs | Q38555487 | ||
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? | Q38934098 | ||
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types | Q39748970 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 3810108 | |
P577 | publication date | 2018-12-17 | |
P1433 | published in | Disease Markers | Q15756044 |
P1476 | title | Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations | |
P478 | volume | 2018 |
Q90399148 | Pathogenesis and Clinical Management of Uterine Serous Carcinoma |
Q89720874 | Proteogenomic Characterization of Endometrial Carcinoma |
Q90093670 | The role of ubiquitination in tumorigenesis and targeted drug discovery |
Q97524894 | Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer |
Search more.